GYRE

Gyre Therapeutics (GYRE)

About Gyre Therapeutics (GYRE)

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.

Details

Daily high

$7.56

Daily low

$7.18

Price at open

$7.55

52 Week High

$14.42

52 Week Low

$6.11

Market cap

673.5M

Dividend yield

0.00%

Volume

93,711

Avg. volume

64,082

P/E ratio

194.49

Gyre Therapeutics News